The use of a novel non-steroidal mineralocorticoid receptor antagonist finerenone for the treatment of chronic heart failure: A systematic review and meta-analysis

BACKGROUND: The non-steroidal mineralocorticoid receptor antagonist finerenone (BAY 94–8862) has been used to treat chronic heart failure (CHF) with reduced ejection fraction (HFrEF). However, conflicting results were reported for its efficacy and safety. The study aimed to compare the efficacy and...

Descripción completa

Detalles Bibliográficos
Autores principales: Pei, Hui, Wang, Wei, Zhao, Di, Wang, Lei, Su, Guo-Hai, Zhao, Zhuo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2018
Materias:
3400
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5916685/
https://www.ncbi.nlm.nih.gov/pubmed/29668577
http://dx.doi.org/10.1097/MD.0000000000010254

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5916685/
https://www.ncbi.nlm.nih.gov/pubmed/29668577
http://dx.doi.org/10.1097/MD.0000000000010254

Ejemplares similares